Abstract

Premarin: The Intriguing History of a Controversial Drug

Author(s): Vance Dwight A

Issue: Jul/Aug 2007 - Hormone Replacement Therapy

Page(s): 282-286

Download in electronic PDF format for $75
  • Premarin: The Intriguing History of a Controversial Drug Page 1
  • Premarin: The Intriguing History of a Controversial Drug Page 2
  • Premarin: The Intriguing History of a Controversial Drug Page 3
  • Premarin: The Intriguing History of a Controversial Drug Page 4
  • Premarin: The Intriguing History of a Controversial Drug Page 5

Abstract

Premarin, a complex of conjugated equine estrogens manufactured by Wyeth for use as hormone replacement therapy in women, was originally developed by the Canadian pharmaceutical firm Ayerst, McKenna and Harrison. The name Premarin was coined from pregnant mare urine, from which the estrogen complex was isolated. Although the complete composition of Premarin and its active components remains undisclosed or unknown, Wyeth reports that it contains a mixture of 10 estrogens. The history of Premarin is entangled in a fascinating story of human intrigue involving ingenuity, influence, controversy, animal rights, competition, money, protection of stockholders, government regulatory power, patient rights, emotions, greed, power, personal and professional freedom, state rights, and perhaps even, ultimately, constitutional issues. As the saga of Premarin evolves, it no doubt will continue to be one of the more interesting and compelling stories of the practice of pharmacy.

Related Keywords

  • Premarin
  • pregnant mare urine
  • conjugated equine estrogens
  • progestin
  • Prempro
  • hormone replacement therapy
  • HRT
  • U.S. Food and Drug Administration
  • FDA
  • regulation
  • regulatory

Related Categories

  • BUSINESS
  • HISTORY
  • HRT
  • LEGAL
  • ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2007
Pg. 282-286
Premarin: The Intriguing History of a Controversial Drug
Author(s): Vance Dwight A
Sep/Oct 2016
Pg. 359-364
Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1
Author(s): Deleruyelle Laura J
Nov/Dec 2016
Pg. 447-454
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 2
Author(s): Deleruyelle Laura J
Jan/Feb 2017
Pg. 6-16
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 3
Author(s): Deleruyelle Laura J
Sep/Oct 2017
Pg. 356
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Author(s): Allen Loyd V Jr
Jul/Aug 2016
Pg. 351
View Sample
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Author(s): Allen Loyd V Jr
Jan/Feb 2023
Pg. 22-23
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Author(s): Brunner Scott
Jul/Aug 2015
Pg. 303-305
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Author(s): Miller David G
May/Jun 2006
Pg. 175-183
The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States
Author(s): Stephenson Kenna, Jones William, Stephenson Douglas M M
Nov/Dec 2015
Pg. 487-488
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Author(s): Allen Loyd V Jr
Mar/Apr 2017
Pg. 95-102
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Author(s): Yoch Doug
Jul/Aug 2020
Pg. 296-297
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Author(s): Brunner Scott
Jan/Feb 2019
Pg. 32-33
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Author(s): Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
May/Jun 2014
Pg. 208
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Author(s): Miller David G
Jul/Aug 2007
Pg. 326-327
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration
Author(s): Kupiec Tom, Kemp Jesse
Jul/Aug 2003
Pg. 250-256
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1
Author(s): Gillson George R, Zava David T
Jan/Feb 2001
Pg. 52-54
Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2
Author(s): Ford Gina, Garcia Lea
Nov/Dec 2016
Pg. 457-458
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)
Author(s):
Sep/Oct 2015
Pg. 389-390
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Author(s): Allen Loyd V Jr
Jul/Aug 2007
Pg. 350-351
PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1
Author(s): Allen Loyd V Jr